Disease burden

Burden of Acne on the system and on the patient

9.4%

Acne vulgaris (acne) affects an estimated 9.4% of the global population, and it is the 8th most prevalent disease worldwide.3

80%
to
95%

80% to 95% of adolescents in Western industrialized countries are affected by acne to some extent.4

1%
&
5%

Although often perceived as a self-limited disease of adolescence, its prevalence remains high into adulthood. By age 40 years, 1% of men and 5% of women still have lesions.5

Psychological burden for patients

The chronic nature of acne and resultant scarring contribute to significant physical, social, psychological, psychiatric and
economic burdens.6

Explore more
Indication

WINLEVI® (clascoterone) 10 mg/g cream is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.3

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd medical_information@glenmarkpharma.com or call 0800 458 0383.

References

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.

 

  1. Kurokawa I, et al. Dermatol Ther (Heidelb). 2021;11(4):1129-1139.
  2. Tuchayi S, et al. Acne vulgaris. Nat Rev Dis Primers. 2015; 1:15029.
  3. WINLEVI® SPC
  4. Piszczatoski CR, Powell J. Clin Ther. 2021;43(10):1638-1644.
  5. Rosette C, et al. J Drugs Dermatol. 2019;18(5):412-418.
  6. Eichenfield LF, et al. J Drugs Dermatol. 2024;23(1):1278-1283.
  7. Purdy S, DeBerker D. BMJ Clin Evid. 2008;1714.
  8. Zouboulis CC, Bettoli V. Br J Dermatol. 2015;Suppl 1:27-36.
  9. ONS. Estimates of the population for the UK, England, Wales, Scotland and Northern Ireland. Accessed 27 June 2024. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland.
  10. Primary Care Dermatology Society. Acne: acne vulgaris. Accessed 27 June 2024. https://www.pcds.org.uk/clinical-guidance/acne-vulgaris.
  11. Dawson AL, et al. BMJ. 2013;346:f2634.
  12. Layton AM, Thiboutot D, Tan J. Br J Dermatol. 2021;184(2):219-225.
  13. Morshed ASM, et al. Sci Rep. 2023; 13: 21084.
  14. Baldwin, H et al. J Drugs Dermatol. 2023;22(6):582-587.
  15. Del Rosso JQ, Kircik L. J Dermatolog Treat. 2024;35(1):2298878.
  16. Kim HJ, et al. Int J Mol Sci. 2024;25(10):5302.
  17. Hebert A, et al. J Drugs Dermatol. 2023;22(2):174-181.
  18. Hebert A, et al. JAMA Dermatology. 2020;156(6):621–630
  19. Abelson MB, Fink K. (2003). Controlling for the Placebo Effect. Review of Ophthalmology. Accessed 17 October 2024. https://www.reviewofophthalmology.com/article/controlling-for-the-placebo-effect.
  20. Hebert A, et al. JAMA Dermatology. 2020;156(6):621–630 (Supplement 1).
  21. Shergill M, et al. Dermatol Ther (Heidelb). 2024;14:1093–1102.
  22. Eichenfield L, et al. J Am Acad Dermatol. 2020;83(2):477-485.
  23. Mazzetti A, et al. J Drugs Dermatol. 2019;18(6):563.
  24. NICE Clinical Knowledge Summary WINLEVI®

Depicted people are not actual patients.

By clicking this link, you are leaving the WINLEVI® website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to continue, please click Continue, otherwise click Stay on page.